DDrare: Database of Drug Development for Rare Diseases

283. 後天性赤芽球癆
［臨床試験数：17，薬物数：36（DrugBank：19），標的遺伝子数：16，標的パスウェイ数：91］

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AF37702 Injection; AF37702, Hematide; Alemtuzumab; Anti-thymocyte globulin; Bortezomib; Bortezomib/dexamethasone; Campath; Campath, Chemo and/or TBI Allo SCT; Cyclophosphamide; Cyclophosphamide + pred; Cyclosporine; Cyclosporine A; Cyclosporine combine with mycophenolate mofetil; Daclizumab; Dexamethasone; Filgrastim; Fludarabine; Fludarabine Phosphate; Hematide; Hematide, peginesatide; Leucine; Methylprednisolone; Mycophenolate; Mycophenolate mofetil; Other: Laboratory Biomarker Analysis; Peginesatide; Phosphate; Prednisone; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Procedure: Peripheral Blood Stem Cell Transplantation; Radiation: Total Body Irradiation; Radiation: Total-Body Irradiation; Rituximab; Sirolimus; Tacrolimus; Trifluoperazine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03966053 (ClinicalTrials.gov)	September 13, 2019	23/5/2019	The Use of Trifluoperazine in Transfusion Dependent DBA	Phase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia	Diamond Blackfan Anemia;Pure Red Cell Aplasia	Drug: Trifluoperazine	Adrianna Vlachos	NULL	Recruiting	18 Years	65 Years	All	24	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03966053
(ClinicalTrials.gov)

September 13, 2019

23/5/2019

The Use of Trifluoperazine in Transfusion Dependent DBA

Phase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia

Diamond Blackfan Anemia;Pure Red Cell Aplasia

Drug: Trifluoperazine

Adrianna Vlachos

NULL

Recruiting

18 Years

65 Years

All

Phase 1;Phase 2

United States